Metformin Orifarm

Metformin, the active ingredient in Metformin Orifarm, is a biguanide presented as an oral dosage form for oral use. It lowers blood glucose levels and is used to treat type 2 diabetes mellitus in adult patients.

GNH USA supplies Metformin Orifarm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Metformin Orifarm belongs to the biguanide class and is indicated for disorders of glucose metabolism.

- Type 2 diabetes mellitus: improves glycemic control by reducing fasting and post‑prandial blood glucose levels.

Metformin Orifarm may cause a range of adverse reactions.

Common Side Effects: - Gastrointestinal upset: nausea, abdominal discomfort, or diarrhea. - Metallic taste: transient alteration of taste perception. - Vitamin B12 deficiency: reduced absorption with long‑term use. - Weight loss: modest reduction in body weight.

Serious or Rare Side Effects: - Lactic acidosis: rare but potentially fatal metabolic acidosis. - Severe hypoglycemia: usually when combined with other glucose‑lowering agents. - Hepatic dysfunction: elevated liver enzymes in susceptible individuals. - Allergic reactions: rash, pruritus, or angioedema.

Before prescribing Metformin Orifarm, clinicians should consider several safety aspects.

- Renal function: assess creatinine clearance; avoid in severe renal impairment. - Hepatic disease: use with caution in patients with liver dysfunction. - Cardiovascular status: monitor in patients with unstable heart failure. - Alcohol intake: limit consumption to reduce risk of lactic acidosis. - Pregnancy and lactation: evaluate risk‑benefit; data are limited. - Store at ambient temperature: keep below 25 °C, in the original container, protected from moisture and light.

Metformin Orifarm can interact with other medicines, altering its efficacy or safety.

Major Interactions (Avoid): - Iodinated contrast agents: may precipitate acute renal failure, increasing lactic acidosis risk. - Cimetidine: can raise metformin plasma concentrations. - Nucleoside reverse transcriptase inhibitors: may enhance metformin exposure.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may mask hypoglycemia symptoms. - Diuretics: can affect renal clearance of metformin. - ACE inhibitors/ARBs: monitor renal function and electrolytes.